December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Efficacy and Safety of Latanoprost/Timolol Maleate Fixed Combination Verses Timolol Maleate and Brimonidine Given Twice Daily
Author Affiliations & Notes
  • JA Stewart
    Pharmaceutical Research Corp Charleston SC
  • DG Day
    Omni Eye Services Atlanta GA
  • ED Sharpe
    Glaucoma Consultants and Center for Eye Research Mt Pleasant SC
  • WC Stewart
    Carolina Eye Institute University of South Carolina School of Medicine Columbia SC
  • Footnotes
    Commercial Relationships    J.A. Stewart, Pharmacia Corp. F, R; D.G. Day, Pharmacia Corp. F, R; E.D. Sharpe, Pharmacia Corp. F, R; W.C. Stewart, Pharmacia Corp F, R.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3430. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      JA Stewart, DG Day, ED Sharpe, WC Stewart; Efficacy and Safety of Latanoprost/Timolol Maleate Fixed Combination Verses Timolol Maleate and Brimonidine Given Twice Daily . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3430.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To evaluate the efficacy and safety of the latanoprost/timolol maleate fixed combination given once each evening versus brimonidine 0.2% and timolol maleate 0.5% solution given twice daily as concomitant therapy in primary open-angle glaucoma or ocular hypertensive patients. Methods: Qualified subjects were begun on timolol maleate 0.5% twice daily alone for one month, then randomized to either the fixed combination or brimonidine and timolol maleate concomitant therapy for six-weeks, then switched to the other treatment regimen for six weeks. The intraocular pressure was measured every two hours between 08:00 and 20:00 hours at baseline and at the end of Period I and Period II. Results: This study found in 32 subjects that the diurnal curve of the intraocular pressure on timolol maleate alone (20.9 2.8 mm Hg) decreased to 17.9 3.2 mm Hg on the fixed combination and 19.0 2.4 mm Hg on brimonidine and timolol maleate (P = 0.02) At individual time points the intraocular pressures were statistically similar between the groups at the 08:00 trough and 2 and 4 hours after dosing. However, beyond 4 hours after dosing the fixed combination demonstrated lower intraocular pressures at every two-hour time point (P < 0.04). The greatest difference was at +12 hours after dosing (2.3 mm Hg [P < 0.001]). Safety was similar between groups for both solicited and unsolicited side effects. Conclusion: This study suggests that in the afternoon and evening hours the fixed combination latanoprost/timolol maleate reduces the intraocular pressure more than brimonidine and timolol maleate given concomitantly twice daily compared to timolol maleate alone.

Keywords: 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 352 clinical (human) or epidemiologic studies: natural history • 355 clinical (human) or epidemiologic studies: risk factor assessment 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.